AbbVie
Search results
Our products. We offer over 30+ brands treating 60+ conditions from oncology and immunology to aesthetics and eye care. Search our global list of products or filter by therapeutic area. learn more.
Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology.
Allergan Aesthetics develops, manufactures, and markets a portfolio of leading brands and products including facial injectables, body contouring, plastics, skin care, and more.
Allergan is now part of AbbVie. Together, we are dedicating more to R&D to drive tomorrow’s breakthroughs, while helping people live better lives today. With the Allergan acquisition, we are bringing together over 30 brands and leadership positions to expand and diversify our product portfolio.
Nov 30, 2022 · That day, AbbVie officially closed its $63-billion acquisition of Allergan to create a larger, stronger and more diversified global biopharmaceutical company. It was an acquisition that allowed us to grow in numbers and bolster our ability to improve people’s lives worldwide.
May 7, 2024 · LO LOESTRIN FE® and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company. LUMIGAN® bimatoprost ophthalmic solution
May 8, 2020 · AbbVie Completes Transformative Acquisition of Allergan. - Creates biopharmaceutical company with leadership positions in key therapeutic areas: Immunology, Hematologic Oncology, Neuroscience, and Allergan Aesthetics. - Robust portfolio of on-market and pipeline assets well-positioned for sustainable long-term growth.
Allergan, Inc. was an American global pharmaceutical company focused on eye care, neurosciences, medical dermatology, medical aesthetics, breast enhancement, obesity intervention and urologics. Allergan, Inc. was formed in 1948, incorporated in 1950 and became a public company in 1970.
Jul 29, 2022 · A bipartisan group of state attorneys general announced Friday morning that it had struck an agreement in principle with the pharmaceutical company Allergan for $2.37 billion to resolve...
May 5, 2020 · As part of its approach to delivering innovation for better patient care, Allergan has built one of the broadest pharmaceutical and device research and development pipelines in the industry.
